RE: Article including SNG.14 Mar 2021 13:19
Reuters) – The following is a roundup of some of the latest novel coronavirus scientific studies and efforts, Treatments and vaccines for COVID-19, the disease caused by the virus, to find.
Half a year later, COVID-19 patients are still having symptoms
Most of the patients, who were hospitalized with COVID-19, have at least one symptom six months after their illness. This comes from a study in Wuhan, China, emerged, in which the novel coronavirus will end 2019 first appeared. The doctors followed up there 1.733 Patient, diagnosed and hospitalized in January 2020 and May. Six months later 76% at least one symptom, including tiredness or muscle weakness (63%), Difficulty sleeping and having anxiety or depression. Most of the seriously ill had persistent lung problems and chest abnormalities, that could indicate organ damage, while 13% Of the patients, whose kidneys were functioning normally in the hospital, later developed kidney problems, researchers reported in The Lancet on Friday. “We're just getting started, understand some of the long-term effects of COVID-19”, Study co-author Bin Cao of the China-Japan Friendship Hospital in Beijing said in a statement. “Our analysis shows, that most patients continue to live with at least some effects of the virus after leaving the hospital”, which highlights the need for follow-up care after discharge.An experimental inhaled form of interferon, which is being tested in hospital to treat COVID-19 patients, may not have any limitation, the researchers feared. One potential problem with interferon is this, that it increases levels of a protein called ACE2, that the new coronavirus uses as access to cells. The researchers examined cells in test tube experiments, that line the path from the nose to the lungs, and realized, that there are actually two forms of ACE2 – the known and a short form, where the input used by the virus is missing. Interferon increases the short form of ACE2, but not the longer form, which does ______________ mean, that it doesn't seem to elevate the entry points for the virus. “We loved it, to discover a new form of ACE2”, said dr. Jane Lucas from the University of Southampton, who co-led the study reported Monday in Nature Genetics, in a statement. “We believe, that this can have important implications for the treatment of COVID-19 infection.” Synairgen Plc inhaled interferon is being tested in late-stage studies. ((go.nature.com/3oBO9Z0)
The viral load of saliva improves the prediction of the severity of COVID-19
The amount of the new coronavirus in the saliva could support medical care for patients, as it is a better predictor of disease progression than viral load in swab samples, taken from the nose and throat, so the researchers. They examined 26 slightly ill COVID-19 patients, 154 Hospital patients – underneath 63 seriously ill and 23 finally deceased – and 108 uninfected people. The salivary virus load, but not the nasopharyngeal viral load, has been linked to C
Sign In
Follow the stocks
